A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia

Neurology

Volumn 64, Issue 11, 2005, Pages 1949-1951

  Benecke, R ^a   Jost, W H ^b   Kanovsky, P ^c   Ruzicka, E ^d   Comes, G ^e   Grafe, S ^e  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c MASARYK UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; NT 201; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSTONIA; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; MUSCLE WEAKNESS; MYALGIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; XEROSTOMIA;

ANTIBODIES; BOTULINUM TOXIN TYPE A; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; HUMANS; MUSCLE CONTRACTION; NECK MUSCLES; TORTICOLLIS; TREATMENT OUTCOME;

EID: 20444374407     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000163767.99354.C3     Document Type: Article

References (10)

1. Hallett M. One man's poison-clinical applications of botulinum toxin. N Engl J Med 1999;341:118-120.
2. Sharma SK, Singh BR. Immunological properties of HN-33 purified from type A Clostridium botulinum. J Nat Toxins 2000;9:357-362.
3. Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102.
4. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:93-107.
5. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:211-237.
6. Wissel J, Müller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20: 44-49.
7. Jost WH, Kohl A, Brinkmann S, et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT201) compared with commercially available botulinum toxin type A (BOTOX degrees) in healthy volunteers. J Neural Transm 2004;Nov 3:(Epub ahead of print).
8. Merz Pharmaceuticals. Dose-finding study NT 201 in the dystonic sternocleidomastoid muscle. Data on file, Merz Pharmaceuticals, Frankfurt, Germany.
9. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002;249:57-63.
10. Merz Pharmaceuticals. Comparative antigenicity of three preparations of botulinum toxin A in the rabbit. Data on file, Merz Pharmaceuticals, Frankfurt, Germany.